Clear science for curious people
ScienceBlog.com
Writer at Science Blog

ScienceBlog.com

Contributor

Profile →

Health

Shortcut through eyelid gives surgeons less-invasive approach to fix brain fluid leaks

Surgeons at Johns Hopkins have safely and effectively operated inside the brains of a dozen patients by making a small entry incision through the natural creases of an eyelid to reach the skull and deep brain. They say access to the skull and brain through either lid, formally known as a transpalpebral orbitofrontal craniotomy, sharply contrasts with the more laborious, physically damaging and invasive, traditional means of entry used in brain surgery that requires opening the top half of the skull. "Going through the eyelid offers a simpler, more direct route to the middle and front regions of the brain than traditional skull-based surgery," says lead study investigator and facial plastic and reconstructive surgeon Kofi Boahene, M.D. "This minimally invasive approach also avoids the major head trauma typically associated with brain surgery." The new approach eliminates the need for shaving the patient's hair, pulling up the scalp, opening the top half of the skull, and moving aside whole outer sections of the brain in order to operate on the organ's delicate neurological tissue. Writing in a pair of studies, one published in the June issue of the Journal of Otolaryngology -- Head and Neck Surgery and another set to appear in the July issue of Skull Base, the Johns Hopkins team describes what are believed to be the first published cases studies of the procedure, documenting how it was successfully used to repair brain fluid leaks, conduct tissue biopsy and remove tumors. All are common surgeries, but were performed in patients whose complex illnesses made the traditional approach too risky or untenable. The minicraniotomy through the eyelid requires surgeons to remove only a small, half-inch to one-inch-square section of skull bone right above the eyebrow, which is later replaced, to gain access to the body's nervous system control center. Once access to the brain is secured, a microscope- and computer-guided endoscope, fitted with a camera, are used to precisely thread other surgical instruments into the soft tissue to perform the operation, using high-tech maps created by advanced CT and MRI scans of the brain. Boahene says the new approach takes less time to perform, taking on average less than two hours in the operating room as opposed to the traditional four to eight hours; poses less risk of possible infection due to the less-invasive amount of work in opening the skull; and requires less time for recovery in hospital, usually an overnight stay instead of four days or longer in the hospital. The only noticeable hints of any surgery having been performed, he says, are the dissolvable sutures across the eyelid. By contrast, many brain surgeries require lengthy cuts of the skin (with its subsequent scarring) before the scalp can be pulled up. "This new technique does not even leave a noticeable scar, as we are deliberately cutting across the natural creases in the eyelid," says Boahene, an assistant professor at the Johns Hopkins University School of Medicine, who has performed 15 such procedures at Johns Hopkins since 2007. Before the procedure, surgeons check by drawing along the eyelid folds with a black marker, making sure the line is not visible when the patient's eyes are open. The minicraniotomy, Boahene says, does still require an anesthetic, which carries its own risks of complications, and ice packs around the eye to prevent swelling. Among the scenarios highlighted in the new reports for which eyelid entry proved useful was to mend a common postsurgical complication, a cerebrospinal spinal fluid leak into the sinus cavity that had resulted from a previous, more invasive skull surgery. Surgeons were fearful that further swelling from additional skull trauma would hamper the patient's recovery and instead opted for the less-invasive form of surgery to stem the flow. In another instance included in the reports, surgeons were able to remove a potentially cancerous tumor in a baby whose skull and head size were deemed too small to endure the physical trauma associated with major brain surgery. "The transpalpebral approach is a very viable and practical option for thousands of surgeries done each year in the United States that involve problems deeply seated behind the eyes or at the front of the brain," says senior study investigator and neurosurgeon Alfredo Quinones-Hinojosa, M.D. The minicraniotomy can also be used to correct deformities or skull bones broken by trauma and car accidents, says Quinones-Hinojosa, an associate professor at Johns Hopkins. The team's next steps, he adds, are to evaluate and expand the list of procedures for which a transpalpebral orbitofrontal craniotomy is best suited. Under consideration by the group are brain aneurysm repair and removal of larger brain tumors that cannot be more easily reached by traditional skull surgery or by going through the nose and sinus cavities. Funding support for this report was provided The Johns Hopkins Hospital. Besides Boahene and Quinones-Hinojosa, other Hopkins researchers who participated in this study were Michael Lim, M.D., and Eugene Chu, M.D. For additional information, please go to: http://www.hopkinsmedicine.org/otolaryngology/ http://www.hopkinsmedicine.org/minimally_invasive_brain_skull_base_surgery_center/about_us/our_team/otolaryngology_head_neck_surgery/kofi_boahene.html http://www.youtube.com/watch?v=xOthIVAWISc http://www.hopkinsmedicine.org/press_releases/2007/05_14_07.html http://www.hopkinsmedicine.org/neurology_neurosurgery/experts/team_member_profile/36A35BDE9B71CB08318C8F419FD7ACB4/Alfredo_Quinones-Hinojosa

Jun 8, 2010

Health

Biogen Idec and Elan initiate first-of-its-kind patient-reported outcomes research program in MS

CAMBRIDGE, Mass. -- June 8, 2010 -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN), in collaboration with EPI-Q, Inc. and Avatar International, LLC, today announced the launch of My MS Health, a first-of-its-kind, web-based, patient-reported outcomes (PRO) research program. My MS Health is designed to track and provide instant reports on patient function and quality of life (QoL) using validated measures over time. This outcomes research program will assess the impact of using My MS Health on patient-healthcare provider communication, and was developed with guidance from a multidisciplinary steering committee of individuals from healthcare and patient communities, as well as academia. Launched today, interested patients and healthcare providers who meet the research criteria can register for the program at www.mymshealth.org. "My MS Health is a new research tool that may help patients and healthcare providers further communicate about important measures in the management of MS," said Alfred Sandrock, M.D., Ph.D., Senior Vice President of Neurology Research and Development at Biogen Idec. "We believe the patients' perspective on how they feel and function is vital in understanding the overall definition of efficacy in MS therapy." The user-friendly, secure technology platform and design for My MS Health was developed by EPI-Q, Inc., an industry leader in innovative health economics and outcomes research solutions, and Avatar International, LLC, an industry leader in healthcare measurement and quality improvement. In addition, EPI-Q, Inc. and Avatar International, LLC will implement My MS Health and evaluate data collected via the web-based outcomes research program. The multidisciplinary steering committee provided critical advice on design and implementation of My MS Health, including the choice and presentation of appropriate measures to ensure relevance to current medical practice and patient needs. "In developing My MS Health, it was important that all voices -- from medicine to academia to the patient community -- were heard and that their specific needs were identified and incorporated into the program," said John F. Foley, M.D., director, Rocky Mountain Multiple Sclerosis Clinic, Salt Lake City, and a member of the My MS Health steering committee. "While clinical and radiological assessments play a primary role in patient evaluation, patient-reported outcomes can offer valuable, standardized data that can lead to more comprehensive insights into the physical, neurological and psychological dimensions of a patient's experience." The pilot phase of My MS Health, anticipated to continue through the first half of 2011, will be available to more than 2,000 patients with relapsing-remitting multiple sclerosis (RRMS) treated with TYSABRI® (natalizumab) and to physicians who prescribe the drug in the U.S. After the pilot phase, there will be a review of intermediate study results to evaluate potential expansion to all people with MS. Interested patients and healthcare providers who meet the study criteria can register for the program at www.mymshealth.org. My MS Health Enrollment When people with MS enroll in My MS Health, they are prompted to complete a series of self-assessment surveys that help them track the effect of MS on their QoL. These answers are recorded and instantly translated into easy to understand reports that patients can view online to track how they feel and how they are responding to therapy over time. Information also can be shared directly via the website with registered healthcare providers, or the report can be printed and used to prompt or guide discussions at regularly scheduled appointments. PROs are validated measures of patient perspectives and can encompass a range of measures, including health-related QoL, ability to function and perform daily activities and the impact of MS symptoms and treatment on QoL and functioning. About TYSABRI TYSABRI is approved in more than 45 countries. In the U.S., it is approved for relapsing forms of MS and in the European Union for relapsing-remitting MS. Data from the Phase III AFFIRM trial highlights TYSABRI's powerful efficacy. According to that data, which was published in the New England Journal of Medicine, after two years, TYSABRI treatment led to a 68 percent relative reduction (p<0.001) in the annualized relapse rate when compared with placebo and reduced the relative risk of disability progression by 42-54 percent (p<0.001). In post-hoc analyses of the Phase III AFFIRM trial and as published in The Lancet Neurology, 37 percent of TYSABRI-treated patients remained free of their MS activity, based on MRI and clinical measures, compared to seven percent of placebo-treated patients. TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain. The risk of PML increases with increasing duration of use. Other serious adverse events that have occurred in TYSABRI-treated patients include hypersensitivity reactions (e.g., anaphylaxis) and infections, including opportunistic and other atypical infections. Clinically significant liver injury has been reported in patients treated with TYSABRI in the post-marketing setting. Common adverse events reported in TYSABRI-treated MS patients include headache, fatigue, infusion reactions, urinary tract infections, joint and limb pain and rash. TYSABRI is co-marketed by Biogen Idec Inc. and Elan Corporation, plc. For more information about TYSABRI, please visit www.tysabri.com, www.biogenidec.com or www.elan.com, or call 1-800-456-2255. About Multiple Sclerosis MS is a chronic, unpredictable and progressive disease of the central nervous system that causes inflammation and destruction of the myelin sheath -- the protective layer that surrounds the body's nerve fibers. This destruction may result in cognitive impairment, physical disability and fatigue. According to the National MS Society, MS affects about 400,000 people in the United States and more than 2.5 million people worldwide. RRMS affects about 85 percent of the MS population. RRMS is characterized by clearly defined flare-ups followed by periods of partial or complete recovery or remission. About Biogen Idec Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients worldwide benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com. About Elan Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York and Irish Stock Exchanges. For additional information about the company, please visit http://www.elan.com. Safe Harbor This press release contains forward-looking statements about the development of My MS Health. These forward-looking statements speak only as of the date of this press release, and we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise. MEDIA CONTACTS: Biogen Idec Kate Weiss Ph: (617) 914-6524 Elan Mary Stutts Ph: (650) 794-4403 Miriam Mason Ph: (650) 877-7616 INVESTOR CONTACTS: Biogen Idec John Applegate Ph: (617) 679-2812 Kia Khaleghpour Ph: (617) 679-2812 Elan Chris Burns Ph: + 353 1 709 4444 Ph: (800) 252-3526 David Marshall Ph: +353 1 709 4444

Jun 8, 2010

Health

96 percent of vasectomy patients cleared without need for multiple semen samples

Having to provide repeated semen samples following a vasectomy could soon be a thing of the past, after 96 per cent of men were given the all-clear based on a single test three months after surgery. Research from The Netherlands, published in the June issue of the urology journal BJUI, showed that 51 per cent of the 1,073 samples contained no sperm and a further 45 per cent contained less than 100,000 immotile sperm. No paternity was reported in the cleared group after a follow-up of at least a year. "Vasectomy is a minimally invasive surgical procedure that provides a widespread, reliable and relatively easy method of birth control" says co-author Dr Herman van Roijen from the Department of Urology at St Elisabeth Hospital, Tilburg, The Netherlands. "One of the major drawbacks is that a considerable number of men still have a few immotile sperm in their semen for a year or more. Conventional guidelines have stated that clearance can only be given to men who provide one or two sperm-free samples. The fear of legal action if pregnancy does occur has led to very conservative vasectomy protocols. "However, our study -- based on guidelines issued by the Dutch Urological Association -- shows that one semen test is adequate to provide clearance in the vast majority of cases." A two-step process was developed by the research team to analyse the semen samples. The first step was wet slide analysis of the semen samples in a deep chamber to provide a relatively reliable indication of sperm numbers and motility. This showed that 51.2 per cent of the samples were sperm free and 41.5 per cent contained less than 50 immotile sperm, giving an initial clearance rate of 92.7 per cent. The remaining 7.3 per cent were then tested using a Neubauer Haemocytometer, according to guidelines issued by the World Health Organization. This resulted in a further 3.3 per cent being cleared and four per cent being declared potentially fertile. A total of 481 men (44.7 per cent) received clearance with residual immotile sperm still present in their semen. After a follow-up of at least one year, no pregnancies had been reported. "Our study clearly shows that three months after vasectomy about half of our patients were still producing sperm, albeit immotile and in very small numbers" says Dr van Roijen. "In fact, we found even higher percentages than previous studies. "However, our study also showed that these residual sperm are of no clinical consequence." The authors conclude that the era of repeated visits to a clinic to deliver yet another semen sample many months after a vasectomy may now be over. "If the guidelines now being employed in The Netherlands were adopted elsewhere, it could dramatically increase the number of men who could be cleared three months after a vasectomy, having provided just one semen sample" says Dr van Roijen. Notes to editors Clearance after vasectomy with a single semen sample containing < than 100,000 immotile sperm/mL: analysis of 1,073 patients. BJUI. 105, pp1572-1575. (June 2010). DOI: 10.1111/j.1464-410X.2009.09074.x Established in 1929, BJUI is published 23 times a year by Wiley-Blackwell and edited by Professor John Fitzpatrick from Mater Misericordiae University Hospital and University College Dublin, Ireland. It provides its international readership with invaluable practical information on all aspects of urology, including original and investigative articles and illustrated surgery. www.bjui.org Wiley-Blackwell is the international scientific, technical, medical, and scholarly publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world's leading societies. Wiley-Blackwell publishes nearly 1,500 peer-reviewed journals and 1,500+ new books annually in print and online, as well as databases, major reference works and laboratory protocols. For more information, please visit www.wileyblackwell.com or www.interscience.wiley.com

Jun 8, 2010

Brain & Behavior

Study is first to show that highly variable sleep schedules predict elevated suicide risk

WESTCHESTER, IL -- Highly variable sleep schedules predict an elevated risk for suicide independent of depression in actively suicidal young adults, according to a research abstract that will be presented Tuesday, June 8, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC. Results indicate that a sample of actively suicidal undergraduate students had a delayed mean bedtime of 2:08 a.m.; restricted total sleep time of 6.3 hours; and highly variable sleep schedules, with time of mean sleep onset varying by three hours and time of sleep offset varying by 2.8 hours. However, accounting for baseline depression severity, sleep variability was the only sleep measurement to individually predict increases in suicidal risk at one week and three weeks. Sleep irregularity also was the only sleep-related variable to predict greater mood lability, which in turn predicted elevated suicidal symptoms. "To our knowledge, this is the first study to evaluate the unique association between sleep and suicide risk using an objective assessment of sleep and a prospective study design," said principal investigator Rebecca Bernert, PhD, Fellow in the Department of Psychiatry and Behavioral Sciences at Stanford University. "We found that a high degree of irregularity in sleep predicted increases in suicidal symptoms, conferring risk above and beyond the influence of depression. Given that the relationship between sleep disturbances and suicide appears to exist independent of depressed mood, we propose that sleep disturbances may instead confer risk via impaired mood regulation and increased mood lability." The three-week study was conducted at the Florida State University Laboratory for the Study of the Psychology and Neurobiology of Mood Disorders, Suicide, and Related Conditions. Bernert and laboratory director Thomas Joiner, PhD, studied 49 actively suicidal undergraduate students between the ages of 19 and 23 years; 71 percent were female. Symptom severity was assessed at baseline, one week and three weeks using the Beck Depression Inventory and Beck Scale for Suicide. Sleep data were obtained by wrist actigraphy for one week, and sleep variability was calculated as the standard deviation of sleep onsets and offsets, summed. Mood lability was evaluated across the same timeframe using daily visual analogue scale mood ratings. According to Bernert, identifying sleep irregularity as a stand-alone risk factor for suicidal ideation could have important clinical implications. "Compared to other suicide risk factors such as a past suicide attempt, disturbed sleep is modifiable, often visible and amenable to treatment," she said. "In this way, the study of sleep may inform suicide risk assessment and represent a clinically unique opportunity for intervention." In 2007 Bernert and Joiner published a review of the literature on sleep disturbances and suicide risk in the journal Neuropsychiatric Disease and Treatment. Among several theories, underlying neurobiological factors such as serotonergic neurotransmission were proposed to play a role in the relationship between sleep and suicide, although this has yet to be tested. Individuals experiencing emotional distress or a suicidal crisis are encouraged to call the toll-free National Suicide Prevention Lifeline, a 24-hour crisis hotline, at 1-800-873-TALK. Those suffering from persistent sleep problems are encouraged to consult with a sleep expert at one of the 2,000 AASM-accredited sleep disorders centers across the U.S. The study was supported by a National Research Service Award from the National Institutes of Health. The SLEEP 2010 abstract supplement is available for download on the website of the journal Sleep at http://www.journalsleep.org/ViewAbstractSupplement.aspx. A joint venture of the American Academy of Sleep Medicine and the Sleep Research Society, the annual SLEEP meeting brings together an international body of more than 5,000 leading clinicians and scientists in the fields of sleep medicine and sleep research. At SLEEP 2010 more than 1,100 research abstract presentations will showcase new findings that contribute to the understanding of sleep and the effective diagnosis and treatment of sleep disorders such as insomnia, narcolepsy and sleep apnea.

Jun 7, 2010

Brain & Behavior

Planes, trains and automobiles: Traffic noise disturbs sleep, affects morning performance

WESTCHESTER, IL -- Nighttime noise from nearby road traffic, passing trains and overhead planes disturbs sleep and impairs morning performance, according to a research abstract that will be presented Tuesday, June 8, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC. Results indicate that mean reaction time on a morning psychomotor vigilance task slowed significantly by 3.6 ms after exposure to recorded traffic noise during sleep, and the slowing of reaction times was directly and significantly related to increases in both the frequency and sound-pressure level of the nightly noise events. The sound of passing trains caused the highest awakening and arousal probabilities followed by automobile traffic and airplane noise. However, this ranking was not reflected in the measures of morning neurobehavioral performance, as each mode of noise caused a similar level of impairment. Furthermore, exposure to more than one of the three modes of traffic noise did not lead to stronger performance impairments than exposure to only one noise source. "The study demonstrated that traffic noise may disturb sleep and consequently impede recuperation, as was shown by deterioration of neurobehavioral performance," said lead author Dr. Eva-Maria Elmenhorst, postdoctoral research fellow at the German Aerospace Center Institute of Aerospace Medicine in Cologne, Germany. "The study therefore stresses the importance of sleep hygiene in terms of a quiet environment for healthy, undisturbed sleep." Elmenhorst noted that nighttime traffic noise may have even stronger effects on the performance of people who are more susceptible to sleep disturbances. Risk groups include children, shift workers, the elderly and people with chronic medical conditions. The study involved 72 people with an average age of 40 years. Their sleep was monitored by polysomnography for 11 consecutive nights. Recorded traffic noise from airplanes, automobiles and trains was played in the laboratory while they slept. Each mode of traffic noise consisted of eight different noise events played back at five sound pressure levels ranging from 45 to 65 A-weighted decibels for a total of 40 noise events. The study was carefully balanced so that sleeping participants were exposed to one to three modes of traffic noise each night, producing a nightly range of 40 to 120 noise events. The study design also included one control night that was free of traffic noise. Each morning after waking up, participants completed a psychomotor vigilance task, memory search task and unstable tracking task to measure neurobehavioral performance. The American Academy of Sleep Medicine reports that traffic noise is one cause of "environmental sleep disorder," which involves an environmental disturbance that causes a complaint of insomnia or daytime sleepiness. Other common causes include bright light and temperature extremes. White noise, which is produced by combining together all the different frequencies of sound, can be used to drown out other sounds and raise your arousal threshold so that your sleep is less disturbed. White noise is produced by box fans and oscillating fans, sound machines, and special applications for computers and smart phones. In a study published in the February issue of the journal International Archives of Occupational and Environmental Health, Elmenhorst reported that daytime performance was significantly less accurate after nighttime exposure to aircraft noise. In a 2009 study in the journal Aviation, Space and Environmental Medicine, Elmenhorst and colleagues reported on the testing of a simulated "Segmented Continuous Descent Approach," a new noise-reduced approach for aircraft landings. The SLEEP 2010 abstract supplement is available for download on the website of the journal Sleep at http://www.journalsleep.org/ViewAbstractSupplement.aspx. A joint venture of the American Academy of Sleep Medicine and the Sleep Research Society, the annual SLEEP meeting brings together an international body of more than 5,000 leading clinicians and scientists in the fields of sleep medicine and sleep research. At SLEEP 2010 more than 1,100 research abstract presentations will showcase new findings that contribute to the understanding of sleep and the effective diagnosis and treatment of sleep disorders such as insomnia, narcolepsy and sleep apnea.

Jun 7, 2010

Health

Few health reform options would have covered more people at lower cost than new law, study finds

The recently enacted federal health care reform law provides health insurance coverage to the largest number of Americans while keeping federal costs as low as reasonably possible, according to a new analysis from the RAND Corporation. The only alternatives that would have covered more Americans at a lower cost to the federal government were all politically untenable -- substantially higher penalties for those who don't comply with mandates, lower government subsidies and less-generous Medicaid expansion, according to research published in the June edition of the journal Health Affairs. "Of all the proposals on the table that would expand health insurance to more Americans, the final health reform law included those that covered the largest number of people at the lowest cost to the federal government," said Elizabeth A. McGlynn, the study's lead author and a senior researcher at RAND, a nonprofit research organization. The RAND analysis estimates that 28 million Americans will be newly insured by 2016 under the provisions of the Patient Protection and Affordable Care Act. The law builds on the existing structure of health insurance in the United States, which is a combination of private and public sources of coverage. The study examined how the expected outcome of health care reform would have changed if components of the law were structured differently. For example, would more people receive coverage if companies with fewer employees were required to provide health insurance to workers or pay a penalty? And how might the cost to the federal government change if the income level for Medicaid eligibility was raised to a higher level? Researchers simulated more than 2,000 different policy scenarios using the RAND COMPARE microsimulation model, which was designed by RAND to provide independent analysis about how different reform proposals would impact the American health care system. The analysis found that only a few policy scenarios would produce better results than expected under the new health reform law and those scenarios represent only small improvements over what will be expected by 2016. For example, the RAND analysis found that an additional 4 million people would be insured with no additional cost to the federal government if the penalty for individuals who fail to purchase health insurance increased to $1,200 annually per person (from $750 in the law). The analysis also showed that a combination of strategies could cut federal spending by $20 billion annually without decreasing the number of newly insured. But this would require a combination of measures that would place a higher financial burden on the lowest-income segment of the nation's population. "These alternative strategies strike us as politically challenging, if not untenable," McGlynn said. "On balance, the new law appears to have landed on a distinctive plain of the policy frontier where the costs and coverage levels achieved were reasonable enough to secure passage of the law." Other authors of the study are Amado Cordova, Jeffrey Wasserman and Federico Girosi. RAND developed COMPARE to provide objective facts and analysis to inform the dialogue about health policy options. COMPARE is funded by a consortium of individuals, corporations, corporate foundations, private foundations and health system stakeholders. RAND Health, a division of the RAND Corporation, is the nation's largest independent health policy research program, with a broad research portfolio that focuses on quality, costs and health services delivery, among other topics. The RAND Corporation is a nonprofit research organization providing objective analysis and effective solutions that address the challenges facing the public and private sectors around the world. To sign up for RAND e-mail alerts: http://www.rand.org/publications/email.html

Jun 7, 2010

Blog Entry

Getting extra sleep improves the athletic performance of collegiate football players

WESTCHESTER, IL -- Getting extra sleep over an extended period of time improves athletic performance, alertness and mood, according to a research abstract that will be presented Tuesday, June 8, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC. Results indicate that football players' sprint times improved significantly after seven to eight weeks of sleep extension. Average sprint time in the 20-yard shuttle improved from 4.71 seconds to 4.61 seconds, and the average 40-yard dash time decreased from 4.99 seconds to 4.89 seconds. Daytime sleepiness and fatigue also decreased significantly, while vigor scores significantly improved. "Sleep duration may be an important consideration for an athlete's daily training regimen," said lead author Cheri Mah of the Stanford Sleep Disorders Clinic and Research Laboratory in Stanford, Calif. "Furthermore, sleep extension also may contribute to minimizing the effects of accumulated sleep deprivation and thus could be a beneficial strategy for optimal performance." The study involved seven healthy students on the Stanford University football team. Their ages ranged from 18 to 22 years, and they played a variety of positions on the team. Participants maintained their habitual sleep/wake schedule for two weeks at the beginning of the season to establish their baseline measures. "These athletes began their competitive season with moderate levels of daytime sleepiness and fatigue," said Mah. Then the participants extended their sleep for seven to eight weeks during the season, obtaining as much sleep as possible and aiming for a minimum of ten hours of sleep each night. The 20-yard shuttle and 40-yard dash drills, which are used to measure performance at the annual National Football League Scouting Combine, were conducted after every regular practice. The Profile of Mood States (POMS) was administered once a week to monitor changes in mood, and daytime sleepiness was assessed using the Epworth Sleepiness Scale. Participants also completed daily sleep journals, and their daily sleep/wake activity was monitored by actigraphy. "By substantially increasing sleep duration, athletes experienced a decrease in both daytime sleepiness and fatigue and increase in vigor towards the end of their season," said Mah. The results support Mah's previous research at Stanford involving men and women who compete in other sports such as basketball, golf, cross country, and track and field. Last year at SLEEP 2009, she reported that five members of the women's tennis team had faster sprint times and better hitting accuracy after a period of sleep extension. At SLEEP 2008 she reported that sleep extension helped five members of the swim team swim faster, react quicker off the blocks, turn faster and increase their kick strokes. Mah noted that although traditional athletic training regimens typically focus on multiple aspects of physical training, few prioritize adequate sleep as an important component. She offered these tips to help athletes improve their performance by maximizing their sleep: Make sleep a part of your regular training regimen. Extend nightly sleep for several weeks to reduce your sleep debt before competition. Maintain a low sleep debt by obtaining a sufficient amount of nightly sleep (seven to eight hours for adults, nine or more hours for teens and young adults). Keep a regular sleep-wake schedule, going to bed and waking up at the same times every day. Take brief naps to obtain additional sleep during the day, especially if drowsy. The SLEEP 2010 abstract supplement is available for download on the website of the journal Sleep at http://www.journalsleep.org/ViewAbstractSupplement.aspx. A joint venture of the American Academy of Sleep Medicine and the Sleep Research Society, the annual SLEEP meeting brings together an international body of more than 5,000 leading clinicians and scientists in the fields of sleep medicine and sleep research. At SLEEP 2010 more than 1,100 research abstract presentations will showcase new findings that contribute to the understanding of sleep and the effective diagnosis and treatment of sleep disorders such as insomnia, narcolepsy and sleep apnea.

Jun 7, 2010

Blog Entry

The best and worst work schedules: Shift start times can impact sleep and alertness

WESTCHESTER, IL -- Regulations that limit the number of hours worked also should provide guidance for shift start times to maximize workers' sleep opportunity and minimize the risk of on-the-job fatigue, according to a research abstract that will be presented Tuesday, June 8, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC. Results indicate that estimated sleep durations varied from 4.5 hours to eight hours according to the start time of the work shift. The maximum estimated sleep duration occurred when the work shift started between 9 a.m. and 2 p.m., and the minimum estimated sleep duration occurred when the shift began between 8 p.m. and midnight. "Our most interesting finding was that shifts beginning between 8 p.m. and midnight yielded consistently poorer predicted performance and less than adequate predicted total sleep per 24 hours," said lead author Angela Bowen, research assistant at the Sleep and Performance Research Center at Washington State University Spokane. The study also predicted that minimum on-the-job fatigue occurred when the shift started at 9 a.m., and maximum fatigue occurred when the work shift began at 11 p.m. Furthermore, there was a relatively sudden decrease in predicted fatigue for duty periods starting after midnight compared with shifts that started just before midnight. The researchers explained that work schedules with start times after midnight allowed workers to sleep right before the duty period, which meant that they were better-rested when the shift began. In contrast, shifts that started just before midnight did not allow for pre-shift sleep because the timing conflicted with the body's early evening circadian process. The results suggest that in addition to implementing regulations that limit the number of hours worked in a 24-hour period, employers should schedule shift start times in a way that maximizes sleep and alertness. In particular, night shifts that begin after midnight may allow workers to get more sleep and experience less fatigue than shifts that start between 8 p.m. and midnight. "Shifts of equal duration differ in how fatiguing they are depending on the time of day when they are scheduled," said Bowen. "The same limitation on the number of duty hours may be either overly restrictive if during the day or too liberal if during the night." The study used mathematical modeling to predict the effect of shift start time on total off-shift sleep time per 24-hour period and mean on-shift level of fatigue per duty period. The analysis was based on the two-process model of sleep regulation, which instantiates the effects of sleep/wake homeostasis and circadian rhythms on sleep propensity and waking fatigue. Bowen and her research team generated 24 hypothetical work schedules with shift start times that varied by one-hour increments across the 24-hour clock. Each hypothetical work schedule lasted six days, with constant start times and standard, nine-hour shift durations. The model allowed for no sleep during duty periods or during the one hour preceding and following each shift. Sleep duration and fatigue level from the last duty day in each work schedule were examined as a function of duty start time. The American Academy of Sleep Medicine reports that shift work disorder occurs when complaints of insomnia or excessive sleepiness occur in relation to work hours that are scheduled during the usual sleep period. Total sleep time is typically curtailed by one to four hours in night and early-morning shift workers, and sleep quality is perceived as unsatisfactory. Excessive sleepiness usually occurs during work shifts and often is accompanied by reduced alertness and impaired mental ability. In an article published in the January 2009 issue of the Journal of Theoretical Biology, researchers from the Sleep and Performance Research Center at WSU Spokane provided a detailed explanation of the mathematical two-process model of sleep regulation. A review in the October 2009 issue of the journal Industrial Health reports that some individuals are more vulnerable than others to performance impairment due to sleep loss, which complicates the application of "one-size-fits-all" regulations for work hours. The authors proposed that modern fatigue and risk-management strategies should be applied because they allow flexibility to account for individual vulnerability or resilience to the performance consequences of extended work hours and shift-work schedules. The study was supported by the Congressionally Directed Medical Research Programs. The SLEEP 2010 abstract supplement is available for download on the website of the journal SLEEP at http://www.journalsleep.org/ViewAbstractSupplement.aspx. A joint venture of the American Academy of Sleep Medicine and the Sleep Research Society, the annual SLEEP meeting brings together an international body of more than 5,000 leading clinicians and scientists in the fields of sleep medicine and sleep research. At SLEEP 2010 more than 1,100 research abstract presentations will showcase new findings that contribute to the understanding of sleep and the effective diagnosis and treatment of sleep disorders such as insomnia, narcolepsy and sleep apnea.

Jun 7, 2010

Health

Center for Medicare and Medicaid Innovation must implement payment reforms rapidly

New York, NY, June 8, 2010 -- The new Center for Medicare and Medicaid Innovation (CMI) must be inclusive and flexible in developing and implementing payment initiatives, continuously monitor their impact, and rapidly disseminate them if they appear to be successful, in order to realize the potential for improved health care delivery and reduced spending, according to a new Health Affairs article by Commonwealth Fund researchers. In "The Center for Medicare and Medicaid Innovation Will Be Central to Health Reform's Success," Stuart Guterman, Karen Davis, Kristof Stremikis, and Heather Drake lay out a series of recommendations for the CMI which, as described in the Affordable Care Act, is meant to develop innovative ways of providing and paying for health care that have the potential to reduce costs while preserving or enhancing health care quality. The CMI, which will begin full-scale operations as part of the Centers for Medicare and Medicaid Services (CMS) in 2011, will be responsible for developing at least 18 reform models specified in the new law, including: patient-centered medical homes, promotion of care coordination through salary-based payment; community-based health teams to support small-practice medical homes; use of health information technology to coordinate care for the chronically ill, and salary-based payment for physicians. "Changing the way we pay for and provide health care to reward high-quality, efficient care is an essential step toward a high performance health system," said Commonwealth Fund President Karen Davis. "If health reform is to succeed in improving care and curbing spending, this new center must function like a research and development laboratory for health care delivery, designed to discover, support, and disseminate the best and most innovative ideas." The authors recommend that the CMI: Adopt a nimble "innovation with evidence development" approach in which new programs are implemented and continued as long as they show they are improving quality and value, and achieving desired outcomes. This would represent a significant shift from the current process for developing, testing, and evaluating new programs, which often is lengthy and cumbersome. Include among its pilots an array of health care payment models, with the foremost goal being that payments are tied to high quality, efficient care that is patient-centered. Include private sector payers and public health insurance programs including Medicare and Medicaid in pilot initiatives -- the broader the initiative, the greater the impact. Be open to payment reform approaches led by states or private sector entities, taking into account geographic differences in health care and the environments in which care is provided. Ensure transparency by developing explicit criteria for selecting new programs and their participants and putting in place a mechanism to inform policymakers and interested parties about ongoing and planned projects. Guarantee there are systems in place to continuously monitor and identify pilots' successes and failures. Be a partner in the success of pilots, rather than a "hands-off" evaluator, providing regular feedback and technical assistance to pilot participants when needed. Share information and findings with the new Independent Payment Advisory Board, which will be up and running in 2014 and is tasked with reducing Medicare spending growth, to assure that its recommendations designed to control spending are based on the best available information about ongoing and promising initiatives. A related report from The Commonwealth Fund Commission on a High Performance Health System was also released today. Developing Innovative Payment Approaches: The Path To High Performance describes several payment innovations that the CMI should introduce to reward more integrated care and achieve better quality and greater value, such as medical homes, accountable care organizations, and bundled payments. Equally important to the success of theses strategies, the report says, will be the scope of the reforms. The authors say that pilots should not be limited to Medicare but should include Medicaid and other public programs, and private payers, in order to magnify the effects of incentives across different payers, reduce administrative burdens, and address unwarranted variation among different payers. "The new Innovation Center offers CMS an opportunity to be flexible in rapidly spreading promising new pilot programs," said Stuart Guterman, Assistant Vice President for the Commonwealth Fund's Program on Payment System Reform and lead author of both reports. "By developing this center to be quick, responsive, and engaged, CMS can go a long way toward ensuring that the health care system sees the savings health care reform has the capacity to deliver." The Commonwealth Fund is a private foundation supporting independent research on health policy reform and a high performance health system.

Jun 7, 2010

Health

Updated HIV therapy guidelines would reduce risk of transmission, save lives, billions in costs

Vancouver, British Columbia (June 7, 2010) -- Researchers from the BC Centre for Excellence in HIV/AIDS (BC-CfE) and the University of British Columbia today released a comprehensive study revealing that the 2008 IAS-USA therapy guidelines for commencing HIV treatment would create significant benefits for individuals infected with HIV and society as a whole. The peer-reviewed mathematical modeling study, published in the research journal PLoS ONE, shows that full implementation of HIV treatment guidelines updated in 2008 by the International AIDS Society (IAS) would lead to more people entering treatment in British Columbia (B.C.). In addition, the study shows an increase in lives saved, billions of dollars in costs averted, and a significant decrease in HIV infections. "The study results are critically important because they reinforce the significant individual and societal benefits of starting earlier HIV treatment and provide further momentum for treatment as prevention, which -- in the absence of a vaccine or cure -- remains the best way to contain and halt the spread of HIV," said Dr. Julio Montaner, Director, BC Centre for Excellence in HIV/AIDS; President, IAS; and the Chair in AIDS Research and Head of Division of AIDS in the Faculty of Medicine at the University of British Columbia. When the study was conducted, 4,379 people were on highly active antiretroviral therapy (HAART) in B.C. under 2006 guidelines, and an additional 6,781 individuals qualified for treatment based on the 2008 guidelines. Approximately 12,300 people were infected with HIV in B.C. at the end of 2005, with 25 per cent to 30 per cent of HIV-infected individuals unaware of their HIV status. The BC-CfE estimated the impact of HAART expansion in B.C. based on 2008 guidelines for different expansion scenarios, and focused on the 50 per cent and 75 per cent coverage of those medically eligible to receive HAART treatment. All scenarios were compared to the treatment coverage in B.C. under the 2006 IAS guidelines. Results demonstrated that HAART expansion would result in a prompt decrease in HIV/AIDS morbidity and mortality and a decrease in new HIV infections. In five years, if the 50 per cent coverage scenario was adopted, B.C. was expected to avert 1,360 HIV infections, prevent the loss of 4,155 person years of disability and mortality, and avoid approximately $21 million in health care costs. Under this scenario, in 40 years 11,387 new HIV infections would be averted and the equivalent of $4.2 billion in HIV lifetime treatment costs could be avoided. If coverage were increased to 75 per cent of medically eligible people, BC-CfE estimated that 14,911 new HIV infections would be averted in 40 years, representing $5.6 billion in avoided lifetime HIV treatment costs. HAART, the landmark drug cocktail that was partially developed at the BC-CfE, has been adopted in Canada and around the world as the gold standard treatment for HIV. At an individual level, HAART stops HIV from progressing to AIDS, extends life expectancy, and significantly reduces HIV-related morbidity and mortality. At a community level, there is strong and growing evidence that people with HIV who are appropriately treated become dramatically less likely to transmit the virus. The 2008 IAS-USA guidelines substantially expanded eligibility to HAART by, among other factors, raising the CD4 cell count at which treatment starts and recommending immediate treatment for those with underlying health conditions such as cardiovascular disease, HIV-associated nephropathy, and chronic hepatitis B or C. Implementing the revised IAS-USA guidelines for the use of HAART in adults is associated with many challenges, including significant up-front costs. However, the BC-CfE analysis demonstrates that ramping up HAART would be highly cost-effective and cost-averting to the health care system within a decade. This model was based on the epidemic in B.C., which is concentrated among men who have sex with men and injection drug users. Most other parts of the world have generalized epidemics. Such differences should be taken into account when reviewing B.C.'s results in the context of the epidemic in other areas. "HAART expansion based on the 2008 IAS-USA guidelines has tremendous potential to further improve health outcomes among HIV-infected individuals in B.C. and throughout the world," said Montaner. "Furthermore, under the BC-CfE's treatment as prevention program, expanding HAART coverage could substantially change the course of the HIV epidemic by decreasing rates of HIV transmission, tuberculosis, malaria and other infectious diseases and therefore curbing the growth of the HIV epidemic." The HIV epidemic remains challenging. In 2008, an estimated 33 million individuals were living with HIV/AIDS in the world, approximately 2.7 million became HIV infected and two million died from AIDS-related causes. The B.C. provincial government has invested $48 million over four years in a pilot project to expand HAART treatment called Seek and Treat. It will expand access to HIV/AIDS medications among hard-to-reach populations, including sex trade workers, injection drug users and men who have sex with men. By engaging more British Columbians living with HIV/AIDS in HAART, better care will be provided and the treatment will significantly reduce or eliminate the virus' ability to spread. B.C.'s Seek and Treat program is being evaluated as part of the BC-CfE's innovative research program, Seek and Treat for the Optimal Prevention of HIV/AIDS (STOP HIV/AIDS). STOP HIV/AIDS has received a US$2.5 million Avant Garde Award from the US National Institute of Drug Abuse (NIDA) of the National Institutes of Health. Funding for the study regarding the expansion of HAART under the 2008 IAS-USA guidelines was received from NIDA, Canadian Institutes of Health Research and Michael Smith Foundation for Health Research. For a copy of the report, Expanding HAART Treatment to All Currently Eligible Individuals Under the 2008 IAS-USA Guidelines in British Columbia, Canada, please visit http://www.cfenet.ubc.ca/publications/ias-usa-guidelines. Journalists can also link to the scientific article in online versions of their reports: http://dx.plos.org/10.1371/journal.pone.0010991. About the British Columbia Centre for Excellence in HIV/AIDS: The BC Centre for Excellence in HIV/AIDS (BC-CfE) is Canada's largest HIV/AIDS research, treatment and education facility. The BC-CfE is based at St Paul's Hospital, Providence Health Care, a teaching hospital of the University of British Columbia. The BC-CfE is dedicated to improving the health of British Columbians with HIV through developing, monitoring and disseminating comprehensive research and treatment programs for HIV and related diseases. About the University of British Columbia The University of British Columbia is one of Canada's largest and most prestigious public research and teaching institutions. Located in the Pacific Rim gateway of Vancouver, one of the world's great cities, and in the Interior city of Kelowna, UBC is a global centre of research and learning. It offers more than 50,000 students a range of innovative undergraduate, graduate and professional programs in the arts, sciences, medicine, law, commerce and other faculties. UBC consistently attracts more than $450 million per year in research funding from government, non-profit organizations and industry through7,000 grants. About PLoS ONE PLoS ONE is the first journal of primary research from all areas of science to employ a combination of peer review and post-publication rating and commenting, to maximize the impact of every report it publishes. PLoS ONE is published by the Public Library of Science (PLoS), the open-access publisher whose goal is to make the world's scientific and medical literature a public resource.

Jun 7, 2010

Health

Simple eye test measures damage from multiple sclerosis, UT Southwestern researchers find

DALLAS -- June 8, 2010 -- A quick, painless eye measurement shows promise as a way to diagnose multiple sclerosis in its very early stages, and to track the effectiveness of treatments, researchers from UT Southwestern Medical Center have found in a multicenter study. "This technique has the potential to provide a powerful and reliable assessment strategy to measure structural changes in the central nervous system, both for diagnostic purposes and in clinical trials to monitor whether potential treatments can prevent deterioration or restore nerve function," said Dr. Elliot Frohman, professor of neurology and ophthalmology, director of the Multiple Sclerosis Clinical Center at UT Southwestern and co-senior author of the study, which appears in the June issue of Annals of Neurology. The technique, called optical coherence tomography (OCT), reliably measures thinning of the retina in people with multiple sclerosis, the researchers found. "An ophthalmologist might someday be able to use OCT to identify retinal thinning during a routine eye exam and consider MS as a prime diagnosis," Dr. Frohman said. "However, this prospect is a long way off." The retina, which lines the back of the eye, detects light and sends visual information to the brain via the optic nerve. Retinal thinning can occur as a result of multiple sclerosis, but this study, Dr. Frohman said, is the first to track such thinning over time in a single group of patients. The Neurology study involved 299 patients with MS who were tracked for six months to 4.5 years. The researchers found that the retinas thinned significantly with time, and patients often concurrently lost visual sharpness. Overall, the study indicated that OCT is reliable, easy to use and sensitive to changes over time. It could also be used with current clinical measures, the researchers said. Because the retina is easily visible through the pupil, it provides a convenient route for assessing nerve damage, compared with other parts of the body. As a result, retinal measurement might be able to pick up signs of multiple sclerosis before a person develops other symptoms, Dr. Frohman said. OCT machines already are available. Patients look into a device similar to those that measure vision for corrective lenses. Near-infrared light, which is invisible to the eye, penetrates the retina and provides information on its thickness. The measurement takes a few seconds for each eye. In addition to the OCT testing, patients in the latest study looked at eye charts so the researchers could test their vision. Control subjects came from the patients' families and clinics' staff. Future studies are needed to ascertain whether OCT can characterize the effectiveness of treatments, Dr. Frohman said. Other UT Southwestern researchers in neurology involved in the study were Gina Remington, clinical research coordinator; Amy Conger, neuro-ophthalmic imaging specialist; and Teresa Frohman, clinic research manager. The research was a joint project with the University of Pennsylvania School of Medicine and Johns Hopkins University School of Medicine. Researchers from the University of Alabama, Birmingham, also participated. The study was funded by the National Multiple Sclerosis Society, the National Institutes of Health, DAD's Foundation and the McNeill Foundation. Visit http://www.utsouthwestern.org/neurosciences to learn more about clinical services at UT Southwestern in the neurosciences, including MS diagnosis and treatment. Visit http://www.utsouthwestern.org/ophth to learn more about UT Southwestern's clinical services in ophthalmology. This news release is available on our World Wide Web home page at http://www.utsouthwestern.edu/home/news/index.html To automatically receive news releases from UT Southwestern via e-mail, subscribe at www.utsouthwestern.edu/receivenews

Jun 7, 2010

Health

La Jolla Institute scientist leads team which discovers important new player in diabetes onset

SAN DIEGO -- (June 7, 2010) If you think of diabetes onset like an elaborate molecular drama, then a research team led by a La Jolla Institute scientist has unmasked a previously unknown cellular player, which is critical to proper insulin secretion. "Defective insulin secretion is a hallmark of both type 1 and type 2 diabetes," said Catherine Hedrick, Ph.D., a scientist at the La Jolla Institute for Allergy & Immunology, who led the team, which included researchers from the University of Virginia. Working in mouse models, the team discovered that the ABCG1 protein is essential for the beta cells of the pancreas to produce sufficient amounts of insulin. Insulin is needed by the body to convert glucose from food into energy. Problems with insulin production underlie both type 1 and type 2 diabetes. "Based on our studies in mice, we think that some diabetes patients may have reduced expression of ABCG1 which impairs their insulin secretion," said Dr. Hedrick, who has previously published findings showing that type 2 diabetics have lower levels of ABCG1 than non-diabetics. The research team also showed that proper expression of the ABCG1 protein in beta cells could be restored in the mice by treatment with some existing antidiabetic drugs. "Our study suggests that certain existing antidiabetic drugs may also provide therapeutic benefit related to restoring normal levels of ABCG1 protein in beta cells and improving insulin secretion in people with type 2 diabetes," said Dr. Hedrick. "Our research points to the need to investigate this possibility further as well as to explore the potential development of new therapies that boost ABCG1 protein levels and insulin secretion," she said. The finding was published online today in the Journal of Clinical Investigation in a paper titled "An intracellular role for ABCG1-mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic beta cells." Jeff Sturek, Ph.D., from the University of Virginia, was lead author on the paper and Dr. Hedrick, who was a faculty member at the University of Virginia before joining the La Jolla Institute in late 2009, was senior author. Ann Marie Schmidt, Ph.D., the Gerald & Janet Carrus Professor of Surgical Science at Columbia University, who specializes in research on the mechanisms of diabetic complications, called the finding a "very novel and extremely important" discovery illuminating the ABCG1 protein's role in optimizing insulin secretion. "This mechanism may be very helpful for people with type 2 diabetes, but also type 1 because it may extend the period of time before all insulin-producing potential is gone," she said. "While delaying disease onset is important in both types of diabetes, it is particularly critical for type 1 diabetics who tend to manifest diabetes as children and who can suffer more severe disease consequences because of the lifelong nature of their illness and their eventual complete loss of the ability to produce insulin." Matthias von Herrath, M.D., director of the La Jolla Institute's Type 1 Diabetes Research Center, agreed and praised the ABCG1 finding as an important step in understanding the cellular mechanisms of insulin secretion. "Dr. Hedrick's discovery offers important insights on possible ways to increase insulin production, which is key to controlling both types of diabetes," said Dr. von Herrath, who is among the world's leading type 1 diabetes researchers. "We are pleased that she recently joined our Institute and will be contributing to our Center's efforts to combat this terrible disease." Dr. Hedrick, who primarily researches the high correlation between diabetes and heart disease, began studying the ABCG1 protein several years ago as she looked at cholesterol buildup and coronary plaque formation in diabetes sufferers. "The primary, known function of ABCG1 is to remove excess cholesterol from the body. But with this study, we have discovered a new function for the ABCG1 protein. We now know that it is also very important for transport of cholesterol to various membranes within beta cells and, most likely, within other cells," she said. "Everybody thinks cholesterol is bad. But actually, scientists have long known it is an essential component of all cell membranes." Dr. Hedrick and her team at the University of Virginia had heard of studies in diabetes mouse models showing that islet beta cells contained excessive cholesterol. "We wondered if this was somehow related to ABCG1, since its function is to remove excess cholesterol from the cells of the body," she said. "So we decided to investigate." It was a novel idea, since ABCG1 was only known to sit on the plasma membrane of cells and no one had studied ABCG1 function within cells. "One surprising finding from our work is that ABCG1 action in beta cells is actually intracellular," said Dr. Sturek of the University of Virginia. "We found that the majority of ABCG1 actually sits inside the beta cell and that it's really important for delivering cholesterol intracellularly to the insulin granule membranes. Without delivery of cholesterol to these membranes by ABCG1, the insulin granules do not develop or function properly and, as a result, release significantly less insulin. This is particularly interesting because it suggests that we look at intracellular roles for ABCG1 in other cell types." In previous studies, Dr Hedrick and her team had also made the finding that people with type 2 diabetes have relatively low levels of ABCG1. "We theorized that this contributed to higher rates of heart disease among type 2 diabetics since failure to successfully remove cholesterol from arteries can lead to arterial plaque buildup, a key contributor to heart disease." Based on this latest research, Dr. Hedrick believes that boosting the levels of ABCG1 in diabetes patients may benefit sufferers in two ways -- by aiding in reducing arterial plaque buildup and in improving insulin production. About La Jolla Institute Founded in 1988, the La Jolla Institute for Allergy & Immunology is a biomedical research nonprofit focused on improving human health through increased understanding of the immune system. Its scientists carry out research seeking new knowledge leading to the prevention of disease through vaccines and the treatment and cure of infectious diseases, cancer and autoimmune diseases such as rheumatoid arthritis, type 1 (juvenile) diabetes, Crohn's disease and asthma. La Jolla Institute's research staff includes more than 100 Ph.D.s and M.D.s.

Jun 7, 2010

Health

UN-led action plan for maternal, child health 'positive,' says World Vision, but crucial gaps remain

A new United Nations initiative designed to improve global maternal, newborn and child health is a welcome development but neglects to address some important action points, according to World Vision, the world's largest international humanitarian organization focusing on the well-being of children. Formally launched by UN Secretary General Ban Ki-Moon today at the Women Deliver conference in Washington, the new Joint Action Plan calls for all countries to revitalize efforts in further reducing preventable deaths among mothers and children worldwide. UN figures indicate that each year at least 350,000 mothers die, as do nearly 9 million babies and children under age five. "This plan will help the global community build on progress made so far in tackling the needless deaths of mothers and children," says World Vision International President and Chief Executive Officer, Kevin Jenkins. "World Vision commends the Secretary General's leadership in making this health catastrophe a global priority." "We now have plenty of examples showing how even the poorest countries can deliver on their pledges if supported with the right kind of technical expertise and appropriate levels of funding -- and this plan aims to ensure that becomes the norm," said Jenkins. "However, it still leaves some crucial gaps that need to be addressed." "For example, family and community care, a cornerstone of successful public health interventions, must be emphasized" Jenkins said. "To succeed in achieving Millennium Development Goals 4 and 5, health care options must be brought closer to households, and barriers to using these services must be reduced." World Vision's analysis shows that the deaths of 2.5 million children could be prevented each year through simple community-level interventions such as getting children and their mothers to sleep under bed nets, improving basic hygiene, making clean water and oral rehydration salts available, and ensuring pneumonia and malaria are treated promptly. In addition, Jenkins commented that rich countries will need to deliver on pledges already made and ensure that an additional US $42.5 billion in health aid is funded by 2015. At the same time, any global plan should also urge governments to move more quickly toward fulfilling existing promises to allocate 15 percent of their national budgets to health, and to include maternal, newborn and child health in their national poverty reduction strategies. Finally, although it aims to be comprehensive, the Joint Action Plan does not adequately address the need for better coordination of health efforts. For example, a recent World Vision analysis has shown that district medical officers in many countries with high child mortality are burdened with spending more than a quarter of their time producing reports for multiple donors and servicing competing demands from external agencies, instead of devoting that time to addressing their communities' health needs. "This is a regrettable oversight given the recent explosion in the number of global health partnerships," Jenkins said. "Streamlined and coordinated reporting that links investments to health outcomes is needed to bolster accountability and improve effectiveness at the family and community level." World Vision's own Child Health Now campaign, launched in November 2009, has recommitted the organization to aligning its health work to prioritize maternal and child health. "Our Child Health Now campaign -- financed by our pledge of US $1.5 billion over the next 5 years - supports more than 600 health and advocacy staff and more than 70,000 community volunteers in helping priority countries improve their health systems," Jenkins said. "We are determined to make an impact in addressing this fundamental issue of children's well-being." About World Vision: World Vision is a Christian relief, development and advocacy organization dedicated to working with children, families and communities worldwide to overcome poverty and injustice. World Vision serves all people regardless of religion, race, ethnicity or gender. To learn more, see www.worldvision.org. About Child Health Now: To learn more about World Vision's campaign, see www.childhealthnow.com

Jun 7, 2010

Health

Violent video games may increase aggression in some but not others, says new research

WASHINGTON -- Playing violent video games can make some adolescents more hostile, particularly those who are less agreeable, less conscientious and easily angered. But for others, it may offer opportunities to learn new skills and improve social networking. In a special issue of the journal Review of General Psychology, published in June by the American Psychological Association, researchers looked at several studies that examined the potential uses of video games as a way to improve visual/spatial skills, as a health aid to help manage diabetes or pain and as a tool to complement psychotherapy. One study examined the negative effects of violent video games on some people. "Much of the attention to video game research has been negative, focusing on potential harm related to addiction, aggression and lowered school performance," said Christopher J. Ferguson, PhD, of Texas A&M International University and guest editor of the issue. "Recent research has shown that as video games have become more popular, children in the United States and Europe are having fewer behavior problems, are less violent and score better on standardized tests. Violent video games have not created the generation of problem youth so often feared." In contrast, one study in the special issue shows that video game violence can increase aggression in some individuals, depending on their personalities. In his research, Patrick Markey, PhD, determined that a certain combination of personality traits can help predict which young people will be more adversely affected by violent video games. "Previous research has shown us that personality traits like psychoticism and aggressiveness intensify the negative effects of violent video games and we wanted to find out why," said Markey. Markey used the most popular psychological model of personality traits, called the Five-Factor Model, to examine these effects. The model scientifically classifies five personality traits: neuroticism, extraversion, openness to experience, agreeableness and conscientiousness. Analysis of the model showed a "perfect storm" of traits for children who are most likely to become hostile after playing violent video games, according to Markey. Those traits are: high neuroticism (e.g., easily upset, angry, depressed, emotional, etc.), low agreeableness (e.g., little concern for others, indifferent to others feelings, cold, etc.) and low conscientiousness (e.g., break rules, don't keep promises, act without thinking, etc.). Markey then created his own model, focusing on these three traits, and used it to help predict the effects of violent video games in a sample of 118 teenagers. Each participant played a violent or a non-violent video game and had his or her hostility levels assessed. The teenagers who were highly neurotic, less agreeable and less conscientious tended to be most adversely affected by violent video games, whereas participants who did not possess these personality characteristics were either unaffected or only slightly negatively affected by violent video games. "These results suggest that it is the simultaneous combination of these personality traits which yield a more powerful predictor of violent video games," said Markey. "Those who are negatively affected have pre-existing dispositions, which make them susceptible to such violent media." "Violent video games are like peanut butter," said Ferguson. "They are harmless for the vast majority of kids but are harmful to a small minority with pre-existing personality or mental health problems." The special issue also features articles on the positives of video game play, including as a learning tool. For example: Video games serve a wide range of emotional, social and intellectual needs, according to a survey of 1,254 seventh and eighth graders. The study's author, Cheryl Olson, PhD, also offers tips to parents on how to minimize potential harm from video games (i.e., supervised play, asking kids why they play certain games, playing video games with their children). Commercial video games have been shown to help engage and treat patients, especially children, in healthcare settings, according to a research review by Pamela Kato, PhD. For example, some specially tailored video games can help patients with pain management, diabetes treatment and prevention of asthma attacks. Video games in mental health care settings may help young patients become more cooperative and enthusiastic about psychotherapy. T. Atilla Ceranoglu, M.D., found in his research review that video games can complement the psychological assessment of youth by evaluating cognitive skills and help clarify conflicts during the therapy process. Contact Dr. Christopher Ferguson by e-mail at [email protected]; or by phone at (956) 326-2636 or (407) 384-8874 during June 1 -- June 15 Contact Dr. Patrick Markey by e-mail at [email protected]; or by phone at (610) 519-4743. Review of General Psychology Special Issue on Video Games, Vol. 14. No. 2: "Introduction to the Special Issue on Video Games" and "Blazing Angels or Resident Evil? Can Violent Video Games Be a Force for Good?" Christopher J. Ferguson, PhD, Texas A&M International University - http://www.apa.org/pubs/journals/releases/gpr-14-2-66.pdf and http://www.apa.org/pubs/journals/releases/gpr-14-2-68.pdf "Vulnerability to Violent Video Games: A Review and Integration of Personality Research," Patrick M. Markey, PhD, Villanova University; Charlotte N. Markey, PhD, Rutgers University. - http://www.apa.org/pubs/journals/releases/gpr-14-2-82.pdf "Children's Motivations for Video Game Play in the Context of Normal Development," Cheryl K. Olson, M.P.H., Sc.D., Massachusetts General Hospital - http://www.apa.org/pubs/journals/releases/gpr-14-2-180.pdf "Video Games in Health Care: Closing the Gap," Pamela M. Kato, PhD, University Medical Center Utrecht, Netherlands - http://www.apa.org/pubs/journals/releases/gpr-14-2-113.pdf "Video Games in Psychotherapy," T. Atilla Ceranoglu, M.D., Massachusetts General Hospital - http://www.apa.org/pubs/journals/releases/gpr-14-2-141.pdf The American Psychological Association, in Washington, D.C., is the largest scientific and professional organization representing psychology in the United States and is the world's largest association of psychologists. APA's membership includes more than 152,000 researchers, educators, clinicians, consultants and students. Through its divisions in 54 subfields of psychology and affiliations with 60 state, territorial and Canadian provincial associations, APA works to advance psychology as a science, as a profession and as a means of promoting health, education and human welfare.

Jun 7, 2010